Donald Trump, pictured on the roof of the West Wing of the White House on Tuesday, claims he will confirm tariffs on drug imports ‘within the next week or so’ - Samuel Corum/Pool/EPA/Shutterstock Donald Trump has threatened to impose tariffs of up to 250pc on pharmaceutical imports in a major threat to one of Britain’s key sectors. The US president, who has already warned global drugmakers to lower their domestic prices in the US, said he would be announcing tariffs for the industry “within the next week or so”. Such a move could be damaging for the UK, which counts pharma giants AstraZeneca and GSK as two of its largest companies and employs 73,000 people in the sector overall. Britain has signed a trade agreement with the US but the pharmaceutical tariffs are expected to be outside the scope of the agreement, increasing the risk. “We’ll be putting an initially small tariff on pharmaceuticals but in one year, one and a half years maximum it’s going to go to 150pc and then it’s going to go to 250pc,” Mr Trump said in a US television interview on Tuesday. The president added that he would impose tariffs on pharmaceutical imports to the US “because we want pharmaceuticals made in our country”. It marks a fresh threat to the industry, which is awaiting the outcome of an investigation by the US commerce department into the impact of imports on American national security. The US president said the tariffs on pharmaceutical imports would be “a separate class” to a string of tariff deals announced in recent weeks, adding: “These are excluded class, as I call them ... like steel, aluminium, etc.” Mr Trump has repeatedly made threats to impose various levels of tariffs on the industry before changing course. His latest comments on trade levies come just days before his latest tariff deadline on goods entering the US comes into effect on Aug 7. The president was also critical of India after the country’s foreign ministry accused the US and the EU of double standards on buying Russian oil. The US is due to impose 25pc tariffs on imports from India but Trump threatened to lift this further in his latest escalation. “We settled on 25pc but I think I’m going to raise that very substantially over the next 24 hours because they are buying Russian oil, they are fuelling the war machine, and if they’re going do that I’m not going to be happy,” he said, adding that India had “not been a good trading partner”. “The sticking point with India is that tariffs are too high ... They will give us zero tariffs and they’re going to let us go in but that’s not good enough because of what they are doing with oil.” Mr Trump also renewed his attacks on Jerome Powell, the chairman of the Federal Reserve, and repeated his calls for the central bank to cut interest rates. Story Continues “Jay Powell is highly political and I call him ... Too Late Jerome, Too Late Powell,” he said. Mr Trump added that Scott Bessent, the US treasury secretary, “does not want” to be chairman of the Federal Reserve but said that there were four others in the running for the position. Mr Powell’s term as chairman of the Federal Reserve ends in May 2026. View Comments
Trump threatens 250pc tariffs on drug imports
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...